Sign In
Buy ADAG
$3.75
+0.0200 (+0.536%)
At Close: Jul 31, 2026
SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, toda
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
10:41am, Wednesday, 08'th Jan 2025
Here is how Adagene Inc. Sponsored ADR (ADAG) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Adagene (ADAG) This Year?
10:41am, Friday, 06'th Dec 2024
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
10:41am, Wednesday, 20'th Nov 2024
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade -
SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, toda
- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every t
Are Medical Stocks Lagging Adagene (ADAG) This Year?
10:45am, Wednesday, 11'th Sep 2024
Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
10:41am, Monday, 26'th Aug 2024
Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, toda
Adagene to Present at Investor Conferences in June
04:45pm, Wednesday, 22'nd May 2024
SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, to
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
09:00am, Friday, 29'th Mar 2024
- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CR
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
04:01pm, Thursday, 07'th Mar 2024
- Global oncology expert brings deep insight in colorectal cancer and role of CTLA-4 therapy as a cornerstone for combination immunotherapy -
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
08:00am, Tuesday, 27'th Feb 2024
SAN DIEGO and SUZHOU, China, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, toda
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
06:00am, Friday, 09'th Feb 2024
- Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference -
